Relative stability of meningococcal serogroup A and X polysaccharides

Vaccine

Volumn 30, Issue 45, 2012, Pages 6409-6415

  Berti, F ^a   Romano, M R ^a   Micoli, F ^a   Pinto, V ^a   Cappelletti, E ^a   Gavini, M ^a   Proietti, D ^a   Pluschke, G ^b   MacLennan, C A ^a,c   Costantino, P ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Meningococcal vaccines; Neisseria meningitidis; Serogroup A; Serogroup X; Stability

Indexed keywords

GLUCOSAMINE; GLYCOCONJUGATE; MANNOSAMINE; MENA CAPSULAR POLYSACCHARIDE; MENINGOCOCCUS VACCINE; MENX CAPSULAR POLYSACCHARIDE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MENINGOCOCCAL VACCINES; MOLECULAR STRUCTURE; NEISSERIA MENINGITIDIS, SEROGROUP A; POLYSACCHARIDES, BACTERIAL; TEMPERATURE;

EID: 84866539903     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.021     Document Type: Article

References (41)

1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
2. http://www.who.int/nuvi/meningitis/en/index.html.
3. Roberts L. Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?. Science 2010, 330:1466-1467.
4. Lapeyssonnie L. Bull World Health Organ 1963, 28(Suppl.):1-114.
5. Chippaux J.P. Control of meningococcal meningitis outbreaks in sub-Saharan Africa. J Infect Dev Ctries 2008, 2(5):335-345.
6. LaForce M.F., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl. 2):B13-B19.
7. Campagne G., Schuchat A., Djibo S., Ousséini A., Cissé L., Chippaux J.P. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 1999, 77:499-508.
8. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
9. Robbins J.B., Schneerson R., Gotschlich E.C., Mohammed I., Nasidi A., Chippaux J.P., et al. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull World Health Organ 2003, 81:745-750. discussion 751-5.
10. Bundle D.R., Smith I.C., Jennings H.J. Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem 1974, 249:2275-2281.
11. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
12. Menactra: a meningococcal conjugate vaccine. Med Lett Drugs Ther 2005, 47(1206):29-31.
13. A new conjugate meningococcal vaccine (Menveo). Med Lett Drugs Ther 2010, 52(1343):59-60.
14. Miller J.M., Mesaros N., Van Der Wielen M., Baine Y. Conjugate meningococcal vaccines development: gsk biologicals experience. Adv Prev Med 2011, 846756:1-17.
15. Bories S., Slaterus K.W., Faucon R., Audiffren P., Vandekerkove M. Peut-on individualiser deux nouveaux groupes sérologiques de Neisseria meningitidis?. Med Trop (Mars) 1966, 26:603-616.
16. Evans J.R., Artenstein M.S., Hunter D.H. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol 1968, 87:643-646.
17. Gagneux S., Wirth T., Hodgson A., Ehrhard I., Morelli G., Kriz P., et al. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 2002, 8:462-466.
18. del Castillo C.M., Vázquez J.A., Romero J. Pascual A Infections by Neisseria meningitidis serogroup X in Spain. Clin Microbiol Infect 2003, 9:964-965.
19. Chen C., Zhang T.G., Wu J., Chen L.J., Liu J.F., Pang X.H., et al. A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China. Chin Med J 2008, 127:664-666.
20. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Maïnassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
21. Gagneux S.P., Hodgson A., Smith T.A., Wirth T., Ehrhard I., Morelli G., et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002, 185:618-626.
22. Mutonga D.M., Pimentel G., Muindi J., Nzioka C., Mutiso J., Klena J.D., et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg 2009, 80:619-624.
23. Etienne J., Sperber G., Adamou A., Picq J.J. Epidemiological notes: meningococcal meningitis of serogroup X in Niamey (Niger). Med Trop (Mars) 1990, 50:227-229.
24. Delrieu I., Yaro S., Tamekloé T.A., Njanpop-Lafourcade B.M., Tall H., Jaillard P., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6:e19513.
25. Bundle D.R., Jennings H.J., Kenny C.P. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J Biol Chem 1974, 249:4797-4801.
26. Tiesjema R.H., Beuvery E.C., Pas B.J.T.E. Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization. Bull World Health Organ 1977, 55:3578-3648.
27. Teodorović P. Synthesis of oligosaccharides related to the capsular polysaccharide of Neisseria meningitidis serotype A. Doctoral thesis. Stockholm University; 2005.
28. Zon G., Szu S.C., Egan W., Robbins J.D., Robbins J. Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infect Immun 1982, 37:89-103.
29. Egan W., Schneerson R., Werner K.E., Zon G. Structural studies and chemistry of bacterial capsular polysaccharides. Investigations of phosphodiester-linked capsular polysaccharides isolated from Haemophilus influenzae types a, b, c, and f: NMR spectroscopic identification and chemical modification of end groups and the nature of base-catalyzed hydrolytic depolymerization. J Am Chem Soc 1982, 104:2898-2910.
30. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10:691-698.
31. Micoli F., Rondini S., Pisoni I., Giannelli C., Di Cioccio V., Costantino P., et al. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. Vaccine 2012, 30:853-861.
32. Ravenscroft N., Averani G., Bartoloni A., Berti S., Bigio M., Carinci V., et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines. Vaccine 1999, 17:2802-2816.
33. 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr Res 1996, 296:83-96.
34. Guidelines on stability evaluation of vaccines WHO/BS/06.2049; 2006.
35. Bardotti A., Averani G., Berti F., Berti S., Carinci V., D'Ascenzi S., et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 2008, 26:2284-2296.
36. Menveo® [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc.
37. NimenrixTM: Summary of product characteristics.(). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info rmation/human/002226/WC500127663.pdf.
38. March 30, 2007. Approval letter - Menactra®. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm1 31175.htm.
39. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213-220.
40. Tiesjema R.H., Beuvery E.C., te Pas B.J. Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization. Bull World Health Organ 1977, 55:43-48.
41. Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847.